Trinity Biotech reported $5.14M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Abbott USD 6.8B 1.72B Mar/2026
Bayer EUR 5.73B 943M Mar/2026
Bio-Rad Laboratories USD 517M 9.8M Jun/2026
EDAP TMS EUR 15.01M 14.82M Mar/2026
J&J USD 20.42B 1.27B Jun/2026
Mesa Laboratories USD 28.98M 8.55M Dec/2025
OraSure Technologies USD 160.58M 16.38M Jun/2026
Plus Therapeutics USD 3.02M 1.23M Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
Siemens EUR 8.66B 6.6B Mar/2026
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026
Tosoh JPY 179.62B 46.51B Mar/2026
Trinity Biotech USD 5.14M 3.8M Dec/2025
Veracyte USD 299.52M 36.38M Jun/2026